SCHEMBL26789869

SCHEMBL26789869

COC[C@H]1C[C@@H](OS(C)(=O)=O)CN1C(=O)OC(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 5/20 0.35
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
HSD11B1 P28845 1/20 0.34
GPR119 Q8TDV5 5/20 0.34
NR1H3 Q13133 4/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
ABCB1 P08183 1/20 0.33
HCRTR2 O43614 1/20 0.32
MMP2 P08253 1/20 0.32
ANPEP P15144 1/20 0.32
UCHL1 P09936 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9383870 1.00 NR1H2 (0.35) NR1H2CHRM2CHRM1CHRM3HSD11B1
SCHEMBL1439328 1.00 NR1H2 (0.35) NR1H2CHRM2CHRM1CHRM3HSD11B1
SCHEMBL1440010 1.00 NR1H2 (0.35) NR1H2CHRM2CHRM1CHRM3HSD11B1
SCHEMBL5397081 0.91 NR1H2 (0.36) NR1H2CHRM2CHRM1CHRM3HSD11B1
SCHEMBL1902097 0.91 NR1H2 (0.36) NR1H2CHRM2CHRM1CHRM3HSD11B1
SCHEMBL21466110 0.91 NR1H2 (0.36) NR1H2CHRM2CHRM1CHRM3HSD11B1
SCHEMBL2522899 0.91 NR1H2 (0.36) NR1H2CHRM2CHRM1CHRM3HSD11B1
SCHEMBL13662049 0.88 NR1H2 (0.34) NR1H2CHRM2CHRM1CHRM3HSD11B1
SCHEMBL1439431 0.87 NR1H2 (0.43) NR1H2CHRM2CHRM1CHRM3HSD11B1
SCHEMBL7807938 0.87 NR1H2 (0.43) NR1H2CHRM2CHRM1CHRM3HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374015-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES KINNATE BIOPHARMA INC. 2023-11-23 US disclosed
US-20230374015-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES KINNATE BIOPHARMA INC. 2023-11-23 US disclosed
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-09-28 US disclosed
CN-116096707-A Inhibitors of fibroblast growth factor receptor kinase 金耐特生物制药公司 2023-05-09 CN disclosed
EP-4169922-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2023-04-26 EP disclosed
EP-4161657-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES Kinnate Biopharma Inc. (US) 2023-04-12 EP disclosed
WO-2022033532-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海和誉生物医药科技有限公司 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF FGFR3, FGFR1, FGFR4 NR1H2 2196/4885CHRM2 4876/4885CHRM1 4871/4885
US-20230374015-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES FGFR1, FGFR2, FGFR3 NR1H2 1245/4885CHRM2 4864/4885CHRM1 4878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.